428 assets in Triple-Negative Breast Carcinoma

hs-20093

ilb2109

Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide

Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer

Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated

Janx008

jk08

Lbl-024 For

Mdna11

Mnpr-101-Dfo-89Zr

Mnpr-101-Pcta-177Lu

Modi-1 Moditope

Nuv-868

Pepticrad-1

Pidnarulex

Proagio

Revdofilimab

Rezatapopt

sbt6290

Spedox-6

S<Sup>3.15</Sup>,S<Sup>3.22</Sup>,S<Sup>3.29</Sup>-[(1,3,5-Triazinane-1,3,5-Triyl)Tris(3-Oxopropane-3,1-Diyl)]{N-[5-Oxo-5-({L-Valyl-N<Sup>5</Sup>-Carbamoyl-L-Ornithyl[(4-Aminophenyl)Methoxy]Carbonyl-N-Methyl-L-Valyl-Lvalyl-(3R,4S,5S)-3-Methoxy-5-Methyl-4-(Methylamino)Heptanoyl-(2R,3R)-N-[(1S,2R)-1-Hydroxy-1-Phenylpropan-2-Yl]-3-Methoxy-2-Methyl-3-[(2S)-Pyrrolidin-2-Yl]Propanamide}-N2.1-Yl)Pentanoyl]-?-Alanyldecakis(N-Methylglycyl)-L-Alanyl-N6-Carbamimidoyl-L-Lysyl-L-?-Aspartyl-L-Cysteinyl-(4R)-4-Hydroxy-L-Prolyl-L-Leucyl-L-Valyl-L-Asparaginyl-L-Prolyl-L-Leucyl-L-Cysteinyl-L-Leucyl-L-Histidyl-L-Prolyl-D-?-Aspartyl-L-Tryptophyl-N6-Carbamimidoyl-L-Lysyl-Lcysteinamide}

tc-510

Tetrathiomolybdate

Transferrin Receptor-Targeted Liposomal P53 Cdna

Vls-1488

Hmbd-002

177lu-rad204

1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-

[225Ac]Ac-AKY-1189

[64Cu]Cu-AKY-1189

68ga-dfc413

ab598

Abbv-461

Adrx-0706

Amcenestrant

bal0891

Bbi-355

Bbi-825

bg-68501

Bgb-43395

ca9hu-1

Clbr001

ct-202

Dupilumab

Egfr/B7H3 Car-T

Futibatinib

Iti-5000 Tnbc Vaccine

Lnth-2403

mov18 ige

nkt5097 cdk2/cdk4 dual degrader